Manuel Cappellari Selected Research

Manuel Cappellari Research Topics

47	Stroke (Strokes) 08/2022 - 09/2011
37	Ischemic Stroke 06/2022 - 09/2011
23	Atrial Fibrillation 01/2022 - 01/2012
11	Hemorrhage 08/2022 - 02/2013
7	Cerebral Hemorrhage 01/2021 - 09/2011
4	Embolic Stroke 01/2019 - 01/2012
3	Hypertension (High Blood Pressure) 01/2021 - 01/2012
2	Infarction (Infarctions) 08/2022 - 01/2018
2	Blood Vessel Dissection 01/2022 - 10/2017
2	COVID-19 11/2021 - 01/2021
2	Hyperlipidemias (Hyperlipidemia) 04/2021 - 01/2012
2	Heart Failure 04/2021 - 01/2012
2	Neoplasms (Cancer) 12/2020 - 02/2013
2	Brain Ischemia (Cerebral Ischemia) 01/2020 - 01/2019
2	Hyperglycemia 01/2019 - 03/2018
1	Transient Ischemic Attack 01/2022
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 11/2021
1	Myocardial Ischemia (Ischemic Heart Diseases) 04/2021
1	Dementia (Dementias) 04/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021
1	Bacterial Endocarditis 12/2020
1	Liver Diseases (Liver Disease) 12/2020
1	Leukoaraiosis 01/2019
1	Hyperthermia 03/2018
1	Venous Thrombosis (Deep-Vein Thrombosis) 10/2017
1	Patent Foramen Ovale 08/2017
1	Lacunar Stroke 01/2014
1	Hemorrhagic Disorders (Hemorrhagic Diathesis) 02/2013
1	Diabetes Mellitus 01/2012
1	Amyloidosis 06/2011
1	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 06/2011

26	AnticoagulantsIBA 01/2022 - 02/2013
8	Vitamin K FDA Link 01/2022 - 11/2017
8	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021 - 01/2012
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2022 - 09/2011
3	ORALIT (ORS)IBA 08/2022 - 03/2018
3	Dabigatran FDA Link 04/2021 - 05/2017
3	4- Acetamido- 4'- isothiocyanatostilbene- 2,2'- disulfonic Acid (SITS)IBA 01/2019 - 01/2012
3	Blood Glucose (Blood Sugar)IBA 09/2018 - 01/2012
2	LipidsIBA 01/2021 - 01/2020
2	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 10/2016
2	Particulate MatterIBA 09/2018 - 02/2018
2	RivaroxabanIBA 01/2018 - 11/2017
2	apixabanIBA 11/2017 - 09/2017
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2022
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022
1	Aspartic Acid (Aspartate)FDA Link 01/2021
1	Lipoproteins (Lipoprotein)IBA 01/2021
1	Triglycerides (Triacylglycerol)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Apolipoprotein C-IIIIBA 01/2021
1	Heparin (Liquaemin)FDA LinkGeneric 12/2020
1	Anesthetics (Anesthetic Agents)IBA 01/2020
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2019
1	Air Pollutants (Pollutants, Air)IBA 02/2018
1	Nitrogen DioxideIBA 02/2018
1	3-O-(2'-acetoxy)benzoyl-2-glucopyranoseIBA 01/2018
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2018
1	Clopidogrel (Plavix)FDA Link 01/2018
1	idarucizumabIBA 05/2017
1	CholesterolIBA 01/2012
1	Cerebrospinal Fluid ProteinsIBA 06/2011
1	Prealbumin (Transthyretin)IBA 06/2011

20	Thrombectomy 08/2022 - 08/2017
13	Therapeutics 01/2022 - 06/2013
7	Secondary Prevention 01/2022 - 10/2014
2	Punctures 08/2022 - 01/2020
2	Endovascular Procedures 05/2021 - 10/2014
2	Conscious Sedation 11/2020 - 01/2020
2	Local Anesthesia 11/2020 - 01/2020
2	General Anesthesia 11/2020 - 01/2020
2	Thrombolytic Therapy 01/2020 - 01/2012
1	Contraindications 11/2021
1	Conservative Treatment 11/2021
1	Time-to-Treatment 01/2021
1	Aftercare (After-Treatment) 01/2019
1	Activities of Daily Living (ADL) 01/2012